Skip to main content
. 2022 Mar 11;10(3):655. doi: 10.3390/biomedicines10030655
ACT adoptive cell therapy
ADCs antibody-drug conjugated
AP-1 activator protein 1
bFGF basic fibroblast growth factor
BsAb bispecific monoclonal antibodies
BCMA B-cell maturation antigen
BsAb bispecific antibody
BiTEs bispecific T cell engagers
BTLA band T lymphocyte attenuator
CAR-NK chimeric antigen receptor NK cells
CAR-T chimeric antigen receptor T cells
CRS cytokine release syndrome
CTLA-4 cytotoxic T lymphocyte antigen 4
FDA food and drug administration
GvHD graft-versus-host disease
HBV hepatitis B virus
HPV human papillomavirus
HLA human leukocyte antigen
iCasp9 inducible Caspase 9
ICI immune checkpoint inhibitors
IFN interferon
IL interleukin
iPSC induced pluripotent stem cells
LAG-3 lymphocyte activation gene 3 protein
LPD lipid-protamine-DNA
mAb monoclonal antibody
MDSCs myeloid derived suppressor cells
NF-κB nuclear factor kappa B
mRNA messenger RNA
OTOTT on-target-off-tumor-toxicity
OV oncolytic virus
PD-1 programmed cell death protein
PD-L1 programmed cell death protein and its ligand
scFv single chain variable fragment
STAT3 signal transducer and activator of transcription 3
TAM tumor associated macrophages
TGF-β transforming growth factor beta
TIL’s tumor-infiltrating lymphocytes
TIM-3 T-cell immunoglobulin domain and mucin domain protein 3
TME tumor microenvironment
Tregs regulatory T cells
TIGIT T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain
TNF tumor necrosis factor
TRAIL TNF related apoptosis inducing ligand
VEGF vascular endothelial growth factor